The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment
Published version of a preprint
Abstract
A hallmark of pancreatic ductal adenocarcinoma (PDAC) is an exuberant stroma comprised of diverse cell types that enable or suppress tumor progression. Here, we explored the role of oncogenic KRAS in protumorigenic signaling interactions between cancer cells and host cells. We show that KRAS mutation (KRAS*) drives cell-autonomous expression of type I cytokine receptor complexes (IL2rγ–IL4rα and IL2rγ–IL13rα1) in cancer cells that in turn are capable of receiving cytokine growth signals (IL4 or IL13) provided by invading Th2 cells in the microenvironment. Early neoplastic lesions show close proximity of cancer cells harboring KRAS* and Th2 cells producing IL4 and IL13. Activated IL2rγ–IL4rα and IL2rγ–IL13rα1 receptors signal primarily via JAK1–STAT6. Integrated transcriptomic, chromatin occupancy, and metabolomic studies identified MYC as a direct target of activated STAT6 and that MYC drives glycolysis. Thus, paracrine signaling in the tumor microenvironment plays a key role in the KRAS*-driven metabolic reprogramming of PDAC. Significance: Type II cytokines, secreted by Th2 cells in the tumor microenvironment, can stimulate cancer cell–intrinsic MYC transcriptional upregulation to drive glycolysis. This KRAS*-driven heterotypic signaling circuit in the early and advanced tumor microenvironment enables cooperative protumorigenic interactions, providing candidate therapeutic targets in the KRAS* pathway for this intractable disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a KRASG12D mutation driven PDAC mice model, immune suppressive cytokines IL-4 and IL-13 and remodeling of the myeloid cell composition in TME have been demonstrated40,41.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [41]
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Trapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204 · cited 3×
“Five microliters of cells (5 × 105) mixed with 5 μL Matrigel was injected.”
MethodInfluentialDang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390 · cited 1×
“IL4 and IL13 Upregulate MYC to Promote Metabolic Reprogramming Oncogenic MYC is known to cooperate with KRAS* in driving many cancers and contributes to many cancer hallmarks (21, 22), including cancer cell survival (23, 24), cancer initiation and progression (24, 25), and metabolic reprogramming of bioenergetic pathw…”
BackgroundOncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationGlutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
Self-citationChronic inflammation and cytokines in the tumor microenvironment
Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014) · Journal of Immunology Research · doi:10.1155/2014/149185 · Cited by 1,765
Cytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1252 · Cited by 1,660
Genetics and biology of pancreatic ductal adenocarcinomaPreprint
Hezel, A. F., Kimmelman, A. C., Stanger, B. Z., Bardeesy, N. M., & DePinho, R. A. (2006) · Genes & Development · doi:10.1101/gad.1415606 · Cited by 1,611
Self-citationAmir, E.-A. D., Davis, K. L., Tadmor, M. D., Simonds, E. F., Levine, J. H., Bendall, S. C., Shenfeld, D. K., Krishnaswamy, S., Nolan, G. P., & Pe'er, D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2594 · Cited by 1,550 · cited 1×
“Data were analyzed with FlowJo (Tree Star) and viSNE (61).”
MethodDeNardo, D. G., Barreto, J., Andreu, P., Vásquez, L. J., Tawfik, D., Kolhatkar, N. S., & Coussens, L. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.018 · Cited by 1,395
The Pancreas Cancer Microenvironment
Feig, C., Gopinathan, A., Neesse, A., Chan, D. S., Cook, N., & Tuveson, D. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3114 · Cited by 1,316
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., et al. (2014) · Nature · doi:10.1038/nature13611 · Cited by 1,259 · cited 1×
“0001 **** Two-sided Low (1) Medium (2) High (3) N-Normal T-Tumor S eg ar a”
BackgroundSelf-citationNeutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?
Coussens, L. M., Zitvogel, L., & Palucka, A. K. (2013) · Science · doi:10.1126/science.1232227 · Cited by 1,096
Aguirre, A. J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D. A., Horner, J., Redston, M. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1158703 · Cited by 1,033 · cited 2×
“Primary mouse cell lines were established in the laboratory (AK-B6, AK192, HY6468, PJAK4217, PJAK4298) as described previously (34) and were routinely cultured in RPMI 1640 (Invitrogen) 10% FBS (Invitrogen).”
MethodSelf-citationDynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990
Bayne, L. J., Beatty, G. L., Jhala, N., Clark, C. E., Rhim, A. D., Stanger, B. Z., & Vonderheide, R. H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.025 · Cited by 947 · cited 1×
“, have been long associated with the recruitment of leukocytes into the TME, which creates a tumor-permissive niche for cancer cells to thrive (43, 44).”
BackgroundJAKs and STATs in immunity, immunodeficiency, and cancer
O'Shea, J. J., Holland, S. M., & Staudt, L. M. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1202117 · Cited by 927 · cited 1×
“It is well established that ligand-induced dimerization of cytokine receptors leads to cross-phosphorylation of tyrosine residues in JAKs, which in turn interact with the SH2 domain of the STAT transcription factors, leading to STAT phosphorylation, homodimerization, and activation (18).”
BackgroundImmune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki–Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 857
Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer
Davidson, S. M., Papagiannakopoulos, T., Olenchock, B. A., Heyman, J. E., Keibler, M. A., Luengo, A., Bauer, M. R., Jha, A. K., O’Brien, J. P., Pierce, K. A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.007 · Cited by 737 · cited 1×
“This finding aligns convincingly with recent in vivo metabolic studies in various cancer models, where glucose is an important source of energy (39, 40).”
ResultOncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia
Pylayeva-Gupta, Y., Lee, K. E., Hajdu, C. H., Miller, G., & Bar-Sagi, D. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.024 · Cited by 721 · cited 1×
“, have been long associated with the recruitment of leukocytes into the TME, which creates a tumor-permissive niche for cancer cells to thrive (43, 44).”
BackgroundMonte, L. B. D., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H. R., Braga, M., Carlo, V. D., Doglioni, C., & Protti, M. P. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20101876 · Cited by 721
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716 · cited 6×
“On the basis of these findings, we speculated that infiltrating Th2 cells Cytokines Mediated Tumor Progression in PDAC RESEARCH ARTICLE APRIL 2020 CANCER DISCOVERY | 617 Murine T cells are predominantly CD4+ type Analysis of T-cell infiltration (iMC) GATA3+CD4+ T cells infiltrate murine PanIN Pdx1-Cre;LSL-KrasG12D scR…”
BackgroundInfluentialSelf-citationDeficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells
Yuneva, M., Zamboni, N., Oefner, P., Sachidanandam, R., & Lazebnik, Y. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200703099 · Cited by 690 · cited 1×
“IL4 and IL13 Upregulate MYC to Promote Metabolic Reprogramming Oncogenic MYC is known to cooperate with KRAS* in driving many cancers and contributes to many cancer hallmarks (21, 22), including cancer cell survival (23, 24), cancer initiation and progression (24, 25), and metabolic reprogramming of bioenergetic pathw…”
BackgroundHosios, A. M., Hecht, V. C., Danai, L. V., Johnson, M. O., Rathmell, J. C., Steinhauser, M. L., Manalis, S. R., & Vander Heiden, M. G. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.02.012 · Cited by 641 · cited 1×
“This finding aligns convincingly with recent in vivo metabolic studies in various cancer models, where glucose is an important source of energy (39, 40).”
ResultCarstens, J. L., Correa de Sampaio, P., Yang, D., Barua, S., Wang, H., Rao, A., Allison, J. P., LeBleu, V. S., & Kalluri, R. (2017) · Nature Communications · doi:10.1038/ncomms15095 · Cited by 633 · cited 1×
“These findings are consistent with recent reports that antitumor immune response is dependent on the presence of the right proportion of T effector (Th1 and CD8+) cells versus tumor-promoting T (Treg, Th2, Th17) cells (10, 32).”
ResultSelf-citationMYC, Metabolism, Cell Growth, and TumorigenesisPreprint
Dang, C. V. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014217 · Cited by 625 · cited 2×
“Following IL4 treatment, our work confirmed enhanced glycolytic pathway activity followed by an increase in TCA cycle intermediates and diminished PPP intermediates, a feature that is known to be attributed to MYC activation (38).”
BackgroundTissue of origin dictates branched-chain amino acid metabolism in mutant Kras -driven cancers
Mayers, J. R., Torrence, M. E., Danai, L. V., Papagiannakopoulos, T., Davidson, S. M., Bauer, M. R., Lau, A. N., Ji, B. W., Dixit, P. D., Hosios, A. M., et al. (2016) · Science · doi:10.1126/science.aaf5171 · Cited by 582 · cited 1×
“It is interesting to note that in vivo metabolism studies in PDAC and other cancer types have definitively shown both glucose and glutamine are utilized by tumors compared to in vitro where PDAC cells are mostly dependent on glutamine (28, 29).”
BackgroundFunctional role for c-myc in mitogenic response to platelet-derived growth factor
Armelin, H. A., Armelin, M. C. S., Kelly, K., Stewart, T. A., Leder, P., Cochran, B., & Stiles, C. D. (1984) · Nature · doi:10.1038/310655a0 · Cited by 565
Cutting Edge: The Common γ-Chain Is an Indispensable Subunit of the IL-21 Receptor Complex
Asao, H., Okuyama, C., Kumaki, S., Ishii, N., Tsuchiya, S., Foster, D., & Sugamura, K. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.1 · Cited by 540
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Self-citationMcAllister, F., Bailey, J. M., Alsina, J., Nirschl, C. J., Sharma, R., Fan, H., Rattigan, Y., Roeser, J. C., Lankapalli, R. H., Zhang, H., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.014 · Cited by 405 · cited 1×
“Earlier studies have shown that other CD4+ T-cell subtypes, such as Th17 cells, can also infiltrate preneoplastic lesions (48, 49).”
ResultSelf-citationBernard, V., Semaan, A., Huang, J. H., Lucas, F. A. S., Mulu, F. C., Stephens, B. M., Guerrero, P. A., Huang, Y., Zhao, J., Kamyabi, N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1955 · Cited by 387 · cited 2×
“Following resection, pancreatic tissue was delivered to the laboratory on ice and dissociated into single-cell suspensions as described previously (60).”
BackgroundMethodSelf-citationBlando, J., Sharma, A., Higa, M. G., Zhao, H., Vence, L., Yadav, S. S., Kim, J., Sepulveda, A. M., Sharp, M., Maitra, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811067116 · Cited by 334 · cited 2×
“These findings are consistent with recent reports that antitumor immune response is dependent on the presence of the right proportion of T effector (Th1 and CD8+) cells versus tumor-promoting T (Treg, Th2, Th17) cells (10, 32).”
BackgroundResultSelf-citationDirect evidence for cancer-cell-autonomous extracellular protein catabolism in pancreatic tumors
Davidson, S. M., Jonas, O., Keibler, M. A., Hou, H. W., Luengo, A., Mayers, J. R., Wyckoff, J., Del Rosario, A. M., Whitman, M., Chin, C. R., et al. (2017) · Nature Medicine · doi:10.1038/nm.4256 · Cited by 331 · cited 1×
“It is interesting to note that in vivo metabolism studies in PDAC and other cancer types have definitively shown both glucose and glutamine are utilized by tumors compared to in vitro where PDAC cells are mostly dependent on glutamine (28, 29).”
BackgroundThe differential expression of IL-4 and IL-13 and its impact on type-2 immunity
Bao, K., & Reinhardt, R. L. (2015) · Cytokine · doi:10.1016/j.cyto.2015.05.008 · Cited by 316 · cited 1×
“The Th2 cells secrete IL4 and IL13 in a paracrine fashion, polarizing additional naïve CD4+ T cells to Th2 type (31).”
BackgroundThe functional plasticity of T cell subsets
Bluestone, J. A., Mackay, C. R., O’Shea, J. J., & Stockinger, B. (2009) · Nature reviews. Immunology · doi:10.1038/nri2654 · Cited by 286
A unique glucose-dependent apoptotic pathway induced by c-Myc
Shim, H., Chun, Y. S., Lewis, B. C., & Dang, C. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1511 · Cited by 286 · cited 1×
“IL4 and IL13 Upregulate MYC to Promote Metabolic Reprogramming Oncogenic MYC is known to cooperate with KRAS* in driving many cancers and contributes to many cancer hallmarks (21, 22), including cancer cell survival (23, 24), cancer initiation and progression (24, 25), and metabolic reprogramming of bioenergetic pathw…”
BackgroundGenomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer
Dey, P., Baddour, J., Muller, F., Wu, C. C., Wang, H., Liao, W.-T., Lan, Z., Chen, A., Gutschner, T., Kang, Y., et al. (2017) · Nature · doi:10.1038/nature21052 · Cited by 264 · cited 1×
“shRNA and CRISPR/Cas9 Knockdown shRNA knockdown was performed as described previously (64).”
MethodSelf-citationRole of IL-13 in regulation of anti-tumor immunity and tumor growth
Terabe, M., Park, J. M., & Berzofsky, J. A. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0445-0 · Cited by 219
Inflammatory networks and immune surveillance of pancreatic carcinoma
Vonderheide, R. H., & Bayne, L. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.01.006 · Cited by 204
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism
Vaseva, A. V., Blake, D. R., Gilbert, T. S. K., Ng, S., Hostetter, G. H., Azam, S. H., Ozkan‐Dagliyan, I., Gautam, P., Bryant, K. L., Pearce, K. H., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.001 · Cited by 187 · cited 1×
“KRAS is known to regulate MYC protein stability via phosphorylation at site S62 (42), which inhibits proteasomal degradation of MYC.”
BackgroundAlternative activation of tumor-associated macrophages by IL-4
Wang, H., & Joyce, J. A. (2010) · Cell Cycle · doi:10.4161/cc.9.24.14322 · Cited by 180
Self-citationSurvival of pancreatic cancer cells lacking KRAS function
Muzumdar, M. D., Chen, P.-Y., Dorans, K. J., Chung, K. M., Bhutkar, A., Hong, E., Noll, E. M., Sprick, M. R., Trumpp, A., & Jacks, T. (2017) · Nature Communications · doi:10.1038/s41467-017-00942-5 · Cited by 177 · cited 1×
“In addition, although KRAS* is critical for all stages of tumorigenesis from initiation to metastasis, challenges surrounding anti–mutant KRAS therapeutics, coupled with murine studies showing bypass of KRAS* dependency (3, 55), underscore the need for alternative strategies targeting KRAS*dependent circuitry to treat…”
Backgroundc-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle
Wang, H., Mannava, S., Grachtchouk, V., Zhuang, D., Soengas, M. S., Gudkov, A. V., Prochownik, E. V., & Nikiforov, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210823 · Cited by 176
Self-citationZhang, Y., Zoltan, M. A., Riquelme, E. M., Xu, H., Şahin, İ., Castro-Pando, S., Montiel, M. F., Chang, K., Jiang, Z., Ling, J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.041 · Cited by 152 · cited 1×
“Earlier studies have shown that other CD4+ T-cell subtypes, such as Th17 cells, can also infiltrate preneoplastic lesions (48, 49).”
ResultSelf-citationStromal cues regulate the pancreatic cancer epigenome and metabolome
Sherman, M. H., Yu, R. T., Tseng, T. W., Sousa, C. M., Liu, S., Truitt, M. L., He, N., Ding, N., Liddle, C., Atkins, A. R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620164114 · Cited by 147 · cited 1×
“It is well established that pro- and/or antiinflammatory cytokines and chemokines sourced from various immune (50–52) and stromal compartments (53) can shape the TME and ultimately dictate the trajectory of tumor progression.”
BackgroundKoh, C. M., Gürel, B., Sutcliffe, S. S., Aryee, M. J., Schultz, D., Iwata, T., Uemura, M., Zeller, K. I., Anele, U. A., Zheng, Q., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.040 · Cited by 133
IL-4: role in disease and regulation of production
Choi, P., & Reiser, H. (1998) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1998.00690.x · Cited by 131 · cited 1×
“IL4 and IL13 are known to be secreted primarily by Th2-polarized CD4+ T cells and to a lesser extent by mast cells, eosinophils, and stromal cells (30).”
BackgroundDey, P., Ström, A., & Gustafsson, J.-Å. (2013) · Oncogene · doi:10.1038/onc.2013.384 · Cited by 113
Self-citationHurwitz, H. I., Cutsem, E. V., Bendell, J. C., Hidalgo, M. M., Li, C., Salvo, M. G., Macarulla, T. M., Sahai, V., Sama, A. R., Greeno, E. W., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0580-2 · Cited by 113 · cited 1×
“However, the studies were terminated following a planned interim futility/efficacy analysis of JANUS 1, because of lack of increase in OS (56).”
Novel c‐MYC target genes mediate differential effects on cell proliferation and migration
Cappellen, D., Schlange, T., Bauer, M., Maurer, F., & Hynes, N. E. (2006) · EMBO Reports · doi:10.1038/sj.embor.7400849 · Cited by 110 · cited 1×
“IL4 and IL13 Upregulate MYC to Promote Metabolic Reprogramming Oncogenic MYC is known to cooperate with KRAS* in driving many cancers and contributes to many cancer hallmarks (21, 22), including cancer cell survival (23, 24), cancer initiation and progression (24, 25), and metabolic reprogramming of bioenergetic pathw…”
BackgroundDey, P., Jonsson, P., Hartman, J., Williams, C., Ström, A., & Gustafsson, J.-Α. (2012) · Molecular Endocrinology · doi:10.1210/me.2012.1227 · Cited by 110
Self-citationTargeting IL4/IL4R for the treatment of epithelial cancer metastasis
Venmar, K. T., & Fingleton, B. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9747-9 · Cited by 95 · cited 1×
“This study, and the work of others (36), expands the role of IL4 in the context of KRAS*-driven PDAC through its promoting cancer cell proliferation via mutant KRAS–mediated upregulation of cytokine receptors such as IL4R, IL2Rγ, and IL13Rα1, which in turn enables IL4 and IL13 cytokine activation of the JAK1–STAT6–MYC…”
BackgroundImmune infiltrates as predictive markers of survival in pancreatic cancer patients
Protti, M. P., & Monte, L. B. D. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00210 · Cited by 92
Exploiting inflammation for therapeutic gain in pancreatic cancer
Steele, C. W., Jamieson, N. B., Evans, T. R. J., McKay, C. J., Sansom, O. J., Morton, J. P., & Carter, C. R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.24 · Cited by 77
Rajamani, D., & Bhasin, M. (2016) · Genome Medicine · doi:10.1186/s13073-016-0282-3 · Cited by 70 · cited 1×
“Finally, metaanalysis of human PDAC identified IL2Rγ as one of the top 50 most overexpressed genes in PDAC tumors (14).”
BackgroundControl of Cell Proliferation and Growth by Myc Proteins
Bernard, S., & Eilers, M. (2006) · Springer eBooks · doi:10.1007/400_004 · Cited by 48 · cited 1×
“MYC upregulation promotes cancer cell proliferation (37) and metabolic reprogramming characterized by increased glucose utilization as well as activation of the core glycolytic pathway (38).”
BackgroundMikhalkevich, N., Becknell, B., Caligiuri, M. A., Bates, M. D., Harvey, R. P., & Zheng, W.-P. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1553 · Cited by 41 · cited 1×
“Expression of the transcription factors Tbet and GATA3 is used for molecular subtyping of Th1 cells and Th2 cells, respectively (33).”
MethodDose-dependent regulation of target gene expression and cell proliferation by c-Myc levels
Schuhmacher, M., & Eick, D. (2013) · Transcription · doi:10.4161/trns.25907 · Cited by 38 · cited 1×
“As previous work showed that MYC expression has a dose-dependent effect on tumor-cell proliferation (19, 20), the finding that IL4 could elevate Myc expression in PDAC cells reinforces the hypothesis of a tumor-promoting role for IL4.”
BackgroundDose and context dependent effects of Myc on epidermal stem cell proliferation and differentiation
Berta, M., Baker, C. M., Cottle, D. L., & Watt, F. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900047 · Cited by 33 · cited 1×
“As previous work showed that MYC expression has a dose-dependent effect on tumor-cell proliferation (19, 20), the finding that IL4 could elevate Myc expression in PDAC cells reinforces the hypothesis of a tumor-promoting role for IL4.”
BackgroundEagar, T. N., Turley, D. M., Padilla, J., Karandikar, N. J., Tan, L., Bluestone, J. A., & Miller, S. D. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7442 · Cited by 32 · cited 1×
“org anti-CTLA4 therapy (45, 46) and induction of CD8+ T-cell infiltration.”
BackgroundThe role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy
Acker, H. H. V., Campillo-Davó, D., Roex, G., Versteven, M., Smits, E., & Tendeloo, V. F. V. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.05.002 · Cited by 27
CTLA‐4 Engagement Inhibits Th2 but not Th1 Cell Polarisation
Ubaldi, V., Gatta, L., Pace, L., Doria, G., & Pioli, C. (2003) · Journal of Immunology Research · doi:10.1080/10446670310001598519 · Cited by 24 · cited 1×
“org anti-CTLA4 therapy (45, 46) and induction of CD8+ T-cell infiltration.”
BackgroundAyars, M., O’Sullivan, E., Macgregor‐Das, A. M., Shindo, K., Kim, H., Borges, M. W., Yu, J., Hruban, R. H., & Goggins, M. (2017) · Oncotarget · doi:10.18632/oncotarget.19848 · Cited by 23 · cited 1×
“Decreased tumor burden aligns with previous reports that shRNA-mediated IL2Rγ depletion provokes tumor regression (17).”
Cited by
Sorted by citations
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 811
Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer
Alam, A., Levanduski, E., Denz, P. J., Villavicencio, H. S., Bhatta, M., Alhorebi, L., Zhang, Y., Gomez, E. C., Morreale, B. G., Senchanthisai, S., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.003 · Cited by 372
Self-citationCell death in pancreatic cancer: from pathogenesis to therapy
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 344
Metabolic Codependencies in the Tumor Microenvironment
Dey, P., Kimmelman, A. C., & DePinho, R. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1211 · Cited by 349
Self-citationSTAT proteins in cancer: orchestration of metabolism
Li, Y., Zhang, C., Martincuks, A., Herrmann, A., & Yu, H. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-022-00537-3 · Cited by 305
Metadata
- Authors
- Dey, P., Li, J., Zhang, J., Chaurasiya, S., Strom, A., Wang, H., Liao, W.-T., Cavallaro, F., Denz, P., Bernard, V., Yen, E.-Y., Genovese, G., Gulhati, P., Liu, J., Chakravarti, D., Deng, P., Zhang, T., Carbone, F., Chang, Q., Ying, H., Shang, X., Spring, D. J., Ghosh, B., Putluri, N., Maitra, A., Wang, Y. A., & DePinho, R. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of Houston (US)
- 3Center for Nuclear Receptor and Cell Signaling, University of Houston, Houston, Texas.
- 1Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Roswell Park Comprehensive Cancer Center (US)
- Baylor College of Medicine (US)
- Corresponding author
- DePinho, Ronald A.
- ORCID
- Dey, Prasenjit
- Li, Jun
- Zhang, Jianhua
- Chaurasiya, Surendra
- Wang, Huamin
- Liao, Wen-Ting
- Cavallaro, Frederick
- Denz, Parker
- Bernard, Vincent
- Yen, Er-Yen
- Genovese, Giannicola
- Gulhati, Pat
- Liu, Jielin
- Chakravarti, Deepavali
- Deng, Pingna
- Zhang, Tingxin
- Carbone, Federica
- Chang, Qing
- Ying, Haoqiang
- Shang, Xiaoying
- Spring, Denise J.
- Putluri, Nagireddy
- Maitra, Anirban
- Wang, Y. Alan
- DePinho, Ronald A.
- Venue
- Cancer Discovery
- Published
- 2020-04-01
- Volume
- 10
- Issue
- 4
- Pages
- 608-625
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3006227213
- Cited by
- 213
- References
- 65
- Citations by year
- 2026: 30 · 2025: 33 · 2024: 33 · 2023: 33 · 2022: 40 · 2021: 36 · 2020: 8
- FWCI
- 10.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- MD Anderson (P30CA16672)
- Baylor College of Medicine (P30CA125123)
- CPRIT (RP170005, RP140106170067, 170067)
- NCI (P01 CA117969, R01 CA225955)
- DOD (W81XWH-14-1-0429, K99/R00, 1K99 CA218891-01A1, U24 CA224020, R01 CA218004, R01 CA304969)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- pancreatic ductal adenocarcinoma, oncogenic KRAS, tumor microenvironment, metabolic reprogramming, glycolysis, c-Myc, STAT6, IL-4, IL-13, Th2 cells, paracrine signaling, tumor stroma
- MeSH terms
- Animals, Humans, Oncogenes, Pancreatic Neoplasms, Transfection, Cytokines, Proto-Oncogene Proteins p21(ras), Mice, Tumor Microenvironment, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
